The Spain-based nutraceutical ingredient supplier has secured exclusive distribution rights to Myota’s patented Metabolic Regulator blend across the United States, United Kingdom, and European Union, excluding Germany and Austria. Based on channel performance and demand insights, the company will also explore expansion opportunities in the APAC and LATAM regions.
The agreement ensures full commercial protection for Suannutra and includes co-developed and customized blends, Maria Ángeles Gutiérrez Montero, business development director for SuanNutra, told NutraIngredients.
The company plans to leverage its global sales and marketing network, which includes SuanNutra USA, Gonmisol Europe and Monteloeder Global, to integrate Myota’s branding into its commercial collateral and digital platforms.
“Adding Myota’s prebiotic fiber blends diversifies Suannutra’s functional ingredient portfolio, complementing existing botanical and specialty formulations and reinforcing its position as a one-stop nutraceutical hub,” Gutiérrez Montero said.
Myota
The UK-based prebiotic blend brand launched in 2019 following almost a decade of research at MIT.
Its product range includes Immunity Booster, formulated with resistance starch, FOS, inulin and partially hydrolyzed guar gum (PHGG); its patented Metabolic Booster, which additionally contains non-fermentable fibers like oat and wheat to support blood sugar and cholesterol levels; and the Gut Booster, with low FODMAP fibers to cater to consumers with gut conditions such as IBS.
Research on Metabolic Booster has shown potential benefits in individuals with pre-diabetes, particularly I’m improving improving clinical biomarkers related to glycemic responses such as HbA1c, oral glucose tolerance and fasting blood glucose. Findings also suggest that it may help improve mood and reduce stress and anxiety, as indicated by changes in inflammation markers and lipid profiles.
The blends will now be offered as ingredients for final product formulation under the names Metabolic Regulator, Digestive Blend and Immune blend.
Synergistic offerings
As Gutiérrez Montero explained, the collaboration looks to solidify Suannutra’s targeted microbiome solutions for cardiometabolic wellness.
Myota’s patented blend of nine plant-based fibers is formulated to maximize SCFA production (butyrate, acetate, propionate) across diverse microbiomes through targeted fermentation by gut microbiota, while Suannutra’s flagship ingredient, Metabolaid, has been shown to indirectly support SCFA generation via microbiome modulation.
These SCFAs play a key role in the stimulation of GLP-1, activating the AMPK pathway and helping maintain healthy lipid metabolism and blood pressure levels, Gutiérrez Montero explained.
“Together, these technologies deliver a synergistic, multi-pathway approach to metabolic health—enhancing prebiotic action at the gut level and supporting systemic metabolic balance,” she said.
“By combining Metabolaid’s support of key metabolic pathways with Myota’s microbiome-driven prebiotic approach, we’re delivering a complementary dual-action approach to today’s metabolic health needs.”
Thomas Gurry, PhD, CEO of Myota, said of the collaboration: “We see immense value in pairing our fermentation-optimized prebiotics with Suannutra’s clinically vetted actives. Together, we are shifting the paradigm from generic gut health to precision-formulated, systemic wellness.”
Consumer demand
As Gutiérrez Montero noted, distribution communication will look different across the territories, and response is likely to be varied.
“In the US, messaging will emphasize FDA-compliant clinical endpoints and consumer-friendly claims on weight and glycemic support,” she said. “In the UK and EU, communications will highlight EFSA-aligned data, low-FODMAP certification and gut microbiome benefits.”
She noted that early enthusiasm is expected in North America, the UK and Scandinavia, where “consumer demand for scientifically validated gut-health solutions is highest.”